Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01869634 · ClinicalTrials.gov registry record · Phase 4
Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART
A Phase 4 study, sponsored by University of California, Davis.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT01869634 is a Phase 4 study that has completed, run by University of California, Davis. The registered enrollment target is 37 participants.
The verdict
NCT01869634, a Phase 4 study, has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disease (CVD) risk.
Interventions
- DRUG darunavir with ritonavir and fixed-dose viread+emtricitabine daily
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-06 |
| Est. Completion | 2016-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01869634
The ClinicalTrials.gov registry entry for NCT01869634 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which darunavir with ritonavir and fixed-dose viread+emtricitabine daily is the first listed.
NCT01869634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01869634 about?
NCT01869634 is a clinical study titled "Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART". Potent HIV suppression with Darunavir-based antiretroviral therapy (ART) will lead to repopulation of gastrointestinal-associated lymphoid tissue (GALT) cluster of differentiation (CD)4+ T-cell populations, normalization of systemic immune activation, and improved HIV-associated cardiovascular disea...
What is the current status of trial NCT01869634?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2013-06. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01869634?
The interventions under investigation include: darunavir with ritonavir and fixed-dose viread+emtricitabine daily (DRUG).
Who is sponsoring clinical trial NCT01869634?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.